Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The picture to keep: oral semaglutide is a slow-moving medicine wearing a daily disguise
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial PMID: 37385280 Lancet
This guide covers every element of switching between GLP-1 compounds , with specific protocols, dose mapping, timeline expectations, and the science behind why the glucagon receptor makes retatrutide a compelling option for people who have hit their ceiling on tirzepatide
Here's how they compare: Wegovy (high-dose semaglutide): About 3% reported hair loss in trials Mounjaro (tirzepatide): About 5.7% on the highest dose reported hair loss Ozempic (lower-dose semaglutide): Hair loss isnt commonly reported (likely because weight loss occurs more moderately) Older GLP-1s like Saxenda (liraglutide): Clinical trials show minimal hair loss reports The key factor seems to be how much and how quickly you lose weight rather than which specific medication you take
L-carnitine supplementation in the research protocol of canine dilated cardiomyopathy [PMID: 1949496] Laboratory literature summary: L-carnitine supplementation in the research protocol of canine dilated cardiomyopathy
Serious adverse effects have not been widely reported, but long-term safety data in humans is lacking
